IBRN - ETF AI Analysis

Top Page

iShares Neuroscience and Healthcare ETF (IBRN)

Rating:55Neutral

Price Target:―

The iShares Neuroscience and Healthcare ETF (IBRN) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Catalyst Pharma and Argenx Se stand out as key contributors to the fund's performance, driven by strong financial health, revenue growth, and strategic advancements. However, weaker holdings like Xenon and Scholar Rock, which face significant financial and operational challenges, weigh on the ETF's overall rating. A notable risk factor is the fund's concentration in companies with high leverage and cash flow issues, which could impact stability during market downturns.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid returns year-to-date, indicating strong momentum in its holdings.

Focused Healthcare Exposure

With over 91% of assets in healthcare, the fund targets a high-growth sector with long-term potential.

Reasonable Expense Ratio

The ETF charges a moderate fee compared to many specialized funds, making it cost-effective for investors.

Negative Factors

Over-Concentration in Healthcare

The fund's heavy focus on healthcare limits diversification and exposes investors to sector-specific risks.

Underperforming Holdings

Several top holdings, including Biogen and Catalyst Pharma, have shown weak or negative performance recently.

Limited International Exposure

With over 81% of assets in U.S. companies, the ETF offers minimal diversification across global markets.

IBRN vs. SPDR S&P 500 ETF (SPY)

AUM4.89M

RegionGlobal

Expense Ratio0.47%

Beta1.10

IssueriShares

Inception DateAug 24, 2022

Dividend Yield1%

Asset ClassEquity

Index TrackedNYSE FactSet Global Neuro Biopharma and MedTech Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume1,460

30 Day Avg. Volume1,230

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

46.13

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering56

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IBRN Summary

The iShares Neuroscience and Healthcare ETF (IBRN) is a fund that focuses on companies in the health care sector, particularly those working on cutting-edge neuroscience, pharmaceuticals, and biotechnology. It tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, giving investors exposure to innovative firms like Biogen and Catalyst Pharma, which are leaders in neurological treatments. This ETF could be appealing for someone looking to invest in medical advancements and diversify their portfolio with health care stocks. However, new investors should know that the fund’s performance is closely tied to the health care sector, which can be volatile and sensitive to regulatory changes.

How much will it cost me?The iShares Neuroscience and Healthcare ETF (IBRN) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to target specific companies in the neuroscience and healthcare fields.

What would affect this ETF?The iShares Neuroscience and Healthcare ETF (IBRN) could benefit from growing global demand for advanced neurological treatments and breakthroughs in biotechnology, as well as increased funding for health care innovation. However, it may face challenges from regulatory hurdles in drug approvals, potential economic slowdowns impacting research budgets, and competition within the pharmaceutical and biotech sectors. Its global exposure and focus on cutting-edge companies provide opportunities but also expose it to risks tied to international market conditions.

IBRN Top 10 Holdings

The iShares Neuroscience and Healthcare ETF (IBRN) is heavily concentrated in the health care sector, with a global mix of companies driving innovation in neuroscience and life sciences. Stocks like Praxis Precision Medicines and ACADIA Pharmaceuticals are rising on the back of promising research and strategic growth initiatives, adding momentum to the fund. However, names like Scholar Rock and Biogen are lagging slightly due to financial underperformance and revenue challenges. With its focus on cutting-edge medical advancements, IBRN offers a compelling but specialized play for investors seeking exposure to transformative health care solutions.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
AXSM	Axsome Therapeutics	4.75%	$226.45K	$8.92B	88.81%	57 Neutral
PRAX	Praxis Precision Medicines	4.60%	$219.61K	$8.18B	328.88%	58 Neutral
ALKS	Alkermes	4.01%	$191.46K	$5.06B	5.40%	80 Outperform
BIIB	Biogen	3.99%	$190.60K	$24.84B	20.08%	74 Outperform
PTCT	PTC Therapeutics	3.97%	$189.25K	$6.21B	82.85%	72 Outperform
SRRK	Scholar Rock Holding	3.95%	$188.39K	$4.65B	2.84%	50 Neutral
ACAD	ACADIA Pharmaceuticals	3.92%	$186.94K	$4.54B	53.40%	75 Outperform
SUPN	Supernus Pharmaceuticals	3.77%	$179.71K	$2.97B	36.78%	55 Neutral
ARGX	Argenx Se	3.65%	$174.26K	$49.76B	21.14%	79 Outperform
XENE	Xenon	3.64%	$173.83K	$3.21B	3.61%	48 Neutral

IBRN Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

30.95

Positive

100DMA

28.92

Positive

200DMA

25.53

Positive

Market Momentum

MACD

0.26

Positive

RSI

53.59

Neutral

STOCH

54.41

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.06, equal to the 50-day MA of 30.95, and equal to the 200-day MA of 25.53, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 54.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRN.

IBRN Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IBRN	―	―	$4.89M	0.47%	―
FMED	―	―	$63.92M	0.50%	―
HRTS	―	―	$56.00M	0.75%	―
HTEC	―	―	$55.79M	0.68%	―
OZEM	―	―	$50.40M	0.59%	―
PSIL	―	―	$19.34M	1.00%	―

Performance Comparison

IBRN

iShares Neuroscience and Healthcare ETF

32.13

7.19

28.83%

FMED

Fidelity Disruptive Medicine ETF

―

HRTS

Tema Cardiovascular and Metabolic ETF

―

HTEC

ROBO Global Healthcare Technology and Innovation ETF

―

OZEM

Roundhill GLP-1 & Weight Loss ETF

―

PSIL

AdvisorShares Psychedelics ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents